For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and Attruby represents a genuine advancement . These novel therapies protect the transthyretin protein, halting its harmful build-up and lessening the severity of the ill